NANTKWEST INC. DL-,0001 Forum: Community User: Ibt2

Am Mittwoch findet der Investors Call statt, um über die Covid-19 Strategie mit ImmunityBio zu reden und zu informieren. Könnte also schon die Tage wieder ordentlich Bewegung in den Kurs kommen.

Danksche für Info 🤗

Am 10.06 ist Shareholders Meeting Event: Annual Shareholders Meeting Date/Time: June 10, 2020 (Time TBA) Location: Virtual (dial-in instructions to follow)

So nun wieder auf WL Sowie Kohle frei wird wird gewagt u wohl auch gewonnen 😉

Schon traurig wie gehässig du geworden bist, seitdem viele Aktien (Sorrento, Nantkwest uvm.) kurstechnisch und prozentual schon lange, an Medigene vorbeigezogen sind. It's just sad to see what happened to you, since you married Medigene... Better file for devorce!

Investor Call, 27.05

Schichte doch einfach um auf Nantkwest, dann gehörst du auch mal zu den Gewinnern...

Nein, da findet die Discussion statt... Leider wieder kein Treffer, Prinzessin Mononoke...

Geil, angegebenes Datum des Links ist der 27.05 !! Na die sind der Zeit aber wirklich voraus...........😁😂🤣

Auch mit 1Mrd. Marktkapitalisierung wäre diese Firma immer noch günstig bewertet. Man muss nur mal die Pipeline, Patrick Soon Shiong+Family und das gesamte Unternehemen betrachten.

https://nantkwest.com/events/nantkwest-and-immunitybio-investor-call-to-discuss-the-companies-covid-19-therapeutic-and-vaccine-initiatives/

27 MAY WEDNESDAY NantKwest and ImmunityBio investor call to discuss the Companies’ COVID-19 therapeutic and vaccine initiatives

Top, danke Lirumlarum 👍

Be The Match BioTherapies®, an organization offering solutions for companies developing and commercializing cell and gene therapies, and NantKwest (Nasdaq: NK), a next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using natural killer (NK) cells to treat cancer and infectious diseases, today announced an agreement through which Be The Match BioTherapies is providing donor material for a NantKwest Phase 1b clinical trial to address acute respiratory distress syndrome (ARDS), one of the primary causes of COVID-19 deaths. The agreement combines Be The Match BioTherapies’ ability to provide high-quality cellular source material from the world’s largest registry of volunteer donors with NantKwest’s capabilities in manufacturing off-the-shelf cell therapies. NantKwest’s allogeneic cell therapy is derived from human bone marrow and designed to treat the ARDS that results from severe COVID-19 cases. The therapy, called BM-Allo.MSC, uses mesenchymal stem cells (MSCs), multipotent progenitor cells known to have immunomodulatory properties, to reduce the lung inflammation associated with ARDS. Similar work in Europe with allogeneic MSC products in patients with COVID-19 and ARDS has demonstrated safety and efficacy in reducing inflammatory processes. NantKwest recently announced FDA authorization of its investigational new drug (IND) application for BM-Allo.MSC and is moving rapidly to initiate a Phase 1b trial in patients with severe COVID-19. To expedite trial initiation, Be The Match BioTherapies is providing cryopreserved donor stem cell material from the Be The Match BioBank, a program of the National Marrow Donor Program ® /Be The Match ®. The accelerated access to material, combined with NantKwest’s scalable manufacturing processes, will allow for rapid distribution of BM-Allo.MSC to patients in need. “There is an immediate need for COVID-19 therapies across all stages of the disease, including for patients with ARDS, which is one of the most critical conditions caused by COVID-19,” said Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of NantKwest. “Thanks to the quality source material provided by Be The Match BioTherapies, we are prepared to rapidly scale manufacturing of this much-needed therapy, potentially saving numerous patients’ lives.” “Through our team’s unparalleled ability to identify, source and deliver high-quality donor material we have the opportunity to support the advancement of a cell therapy with potential to change the world. We are proud to partner with NantKwest to support our mission to save lives through cellular therapy and continue to make a difference for critically ill patients around the globe,” said Chris McClain, Senior Vice President, Sales and New Business Development at Be The Match BioTherapies.

NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients May 18, 2020 | Press Releases NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe  COVID-19 Patients Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm Trial anticipated to initiate in Los Angeles area hospitals in Q2 Proprietary automated “GMP-in-a-Box”, an in-house manufacturing apparatus, enables rapidly scalable, off-the-shelf allogeneic mesenchymal stem cell product BM-Allo.MSC EL SEGUNDO, Calif. May 18, 2020 – NantKwest, Inc. (NASDAQ: NK) today announced it has received authorization from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug application to treat patients with acute respiratory distress syndrome (ARDS) caused by COVID-19 with BM-Allo.MSC, an allogeneic mesenchymal stem cell (MSC) product derived from human bone marrow. NantKwest has entered into an agreement with the National Marrow Donor Program (Be the Match) to provide donor material and has developed automated  proprietary methods to expand and generate multiple dose forms utilizing a modular, closed system (GMP-in-a-box) from NantKwest affiliate ImmunityBio, Inc., to expand BM-Allo.MSCs, enabling the scalable manufacture and immediate distribution of cryopreserved BM-Allo.MSC product. “There is an urgent need to develop broadly accessible treatment options for the devastating outcomes seen in the thousands of COVID-19 patients who are facing severe disease with ARDS and ‘cytopathic storm,’” said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of NantKwest and ImmunityBio. “While MSC-derived treatments have shown promise in treating patients with ARDS, including those with COVID-19, the ability to scale production to support the overwhelming patient need has been a challenge. Our proprietary GMP-in-a-Box enables the rapid and scalable manufacture of our fully human BM-Allo.MSC product, overcoming this previous limitation to advance a promising new treatment to those patients who are most in need. Due to our proprietary methods, we are well positioned to rapidly advance BM-Allo.MSC during the current wave of COVID-19, with an anticipated trial initiation in Q2” BM-Allo.MSC a bone marrow-derived allogenic MSC product being developed to attenuate the inflammatory processes that drive ARDS in severe COVID-19 patients. MSCs are multipotent progenitor cells that give rise to cell types responsible for tissue repair and may restore effective immune function and contribute to viral clearance. Prior work with allogeneic MSC products in patients with ARDS has shown that such treatment is safe and may reduce key markers of inflammatory processes. Trial Design The Phase 1b, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BM-Allo.MSC versus current supporting care in treating patients with severe disease and requiring ventilator support (IND 019735). The therapeutic will be administered to a total of 45 patients receiving care in the critical care or ICU setting. The primary objectives of the study include overall safety and reduction in time on ventilator. The secondary objective will focus on the efficacy of BM-Allo.MSC in reducing the number of days patients require oxygen, duration of hospitalization, and mortality.

Colin Cowherd talks with Dr. Patrick Soon-Shiong who is not only a Doctor helping to fight Covid-19 but also owns the LA Times and is a minority owner of the Lakers. Dr. Shiong talks about the things we are learning about the disease and why it is so much more dangerous than previous pandemics https://podcasts.apple.com/us/podcast/saturday-special-colin-speaks-dr-patrick-soon-shiong/id1042368254?i=1000474797502